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An Interview with Professor Robert J. Lefkowitz, M.D.
Robert J. Lefkowitz, M.D., is James B. Duke Professor of Medicine
and Professor of Biochemistry at the Duke University Medical Cen-
ter. He has been an Investigator of the Howard Hughes Medical In-
stitute since 1976. Dr. Lefkowitz received a Bachelor’s degree from
Columbia College and an M.D. degree from Columbia University
College of Physicians and Surgeons. After serving an internship
and one year of general medical residency at the College of Physi-
cians and Surgeons, he served as a Clinical and Research Associate
with Drs. Jesse Roth and Ira Pastan at the National Institutes of
Health. He then completed his medical residency and research and
clinical training in cardiovascular disease at the Massachusetts
General Hospital, Boston. During this time, he continued his re-
search in the laboratories of Dr. Edgar Haber and was a teaching
fellow at Harvard Medical School. On completing his training, he
was appointed Associate Professor of Medicine and Assistant Pro-
fessor of Biochemistry at the Duke University Medical Center.
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Dr. Lefkowitz, what led to your interest in studying
the G protein-coupled receptor (GPCR) family?
It’s an interesting story. I began my career as a physi-
cian. I went to medical school, not as many aspiring re-
searchers do today, as part of an M.D./Ph.D. program or as
a way of getting some general biological background for a
career in research. I went to medical school to be a prac-
ticing physician; that was all I had in mind. When I fin-
ished medical school and I began my residency, a lot of my
colleagues were looking for ways to avoid going to Viet-
nam. It was the late 1960s, the Vietnam War was at its
peak, and there was a doctor draft going on at that time.
Depending on the arrangements you made, you either did
one year of internship before you went to Vietnam, or two
years if you made special arrangements. One of the attrac-
tive things for someone interested in academia, which I
was—I was thinking about being an academic physician—
was to get some research experience. The typical way to
do that was to be accepted to the NIH, and then to enter
the military via the U.S. Public Health Service, which is
one of the branches of the Armed Forces. In that way, you
could fulfill your military obligation. Since I was a very
good student, I was able to win one of those appointments.
I graduated medical school in 1966, completed an in-
ternship, and went to the NIH on July 1, 1968. One day,
in early 1968, I was sitting in the House Staff library
reading a journal article. This was about four months be-
fore I was to start at the NIH. I happened to read a pa-
per in the Annals of the New York Academy of Sciences
by a very famous scientist named Earl Sutherland, who
was a Nobel Laureate, having won the Nobel Prize for
discovering cyclic AMP. In the article, he talked about
his work on adenylate cyclase; he had shown that cyclic
AMP levels could be raised by things like epinephrine,
through what was called the b-adrenergic receptor. He
speculated that the b-adrenergic receptor was part of the
adenylate cyclase pathway. This was all very interesting
to me.
When I got to the NIH and I talked with my mentors,
Jesse Roth and Ira Pastan, they suggested that I consider
a couple of different projects. One was to see if I could
work out a radioligand binding assay for the adrenocor-
ticotropic hormone (ACTH) receptor. At that time, there
was no direct way to study receptors. Taking into con-
sideration what I had just read about Sutherland’s work,
I had an intuitive feeling that this would be a good area
to study. So I began to study receptors.

Your laboratory is sometimes viewed from the outside
as an “army” of postdocs. What is the average
ongoing size of your lab?
The average census of my lab, and this hasn’t changed
in 25 years, is about 25 people, which includes about
three administrative personnel and six or seven techni-
cians. Everybody else is a postdoc or a student.
Never a lack of applications?
Oh, no, more than I can use. Lately, it has gotten worse,
as many of us have been flooded with applications from
China, via E-mail. I probably get an average of two in-
quiries a day, ten a week, and 90% of those are from China.
Where do your various trainees come from (college,
graduate school, medical school)?
I have several types of trainees. The major denizen of
my laboratory is someone who has just completed his or
her Ph.D. in a field such as biochemistry, pharmacology,
or molecular biology. I also have physician/scientist
trainees, who generally come out of the clinical program
at Duke Medical Center. Over the years, I have had physi-
cian/scientists from virtually every branch of medicine,
every subspecialty. Typically, they are trying to determine
if they want to travel the career path that I did and see if
research is for them. I also have graduate students and
M.D./Ph.D. students and, occasionally, undergraduate stu-
dents who spend a few hours a week in the lab.
When they leave your lab, what types of positions 
do they generally take? Do most of them go into
academia?
Not any more, and that has changed over the years.
When I started the lab in 1973, during the first decade,
nearly 100% of my trainees went into academia. Begin-
ning in the early 1980s, a significant fraction began to go
into the pharmaceutical industry. Now, although they still
go in those same two directions, about 50% go into acad-
emia and 50% go into the private sector, which now di-
vides into two groups, big pharma and biotechnology.
These days, probably the majority of that 50% are going
into biotech. Some of those positions are really quite nice,
as many of the biotechs are almost a hybrid between aca-
demic life and drug company life.
Can you remember all of your trainees? So many of
them have gone on to great success in research. To
what do you attribute that?
That is a very interesting question. I have been re-
markably fortunate. In the area of GPCRs, which is cur-
rently one of the hottest topics and the focus of many
conferences each year, it is not unusual for anywhere
from 25% to 35% of all plenary speakers to be people
who have trained with me over the years. And sometimes
that percentage is even greater. If you look overall at the
attendees at these conferences, the percentage that trained
with me is amazing.
The key issue is why have my trainees had so much
success. I have thought about that a great deal. I really
do think there are key elements about doing good science
that are transferable, but none of those elements can be
written down in a book or even lectured about. They have
to be taught by example. Studying with a research men-
tor like myself is an apprenticeship; you basically live
with the person for three, four, or five years. You watch
what he or she does. Therefore, it is important for the
mentor to share himself with his students. Anybody who
knows me knows that I am extraordinarily interactive. I
thrive on the daily interactions and the relationships. My
trainees get to see me in operation day to day. I do not
function behind closed doors.
For example, for many years I have held small group
meetings in my office three or four afternoons a week.
Typically they last anywhere from two hours to three or
four hours. These are groups of from four to a dozen peo-
ple, sometimes more, who are working on related themes
in the laboratory. We go over data, talk about the results,
and plot strategy. I share myself with them, and they see
me work, making decisions such as what projects to work
on. They learn my thinking style; for example, when do
I abandon a project for which I think there is no hope,
and when do I stick with it even in the face of adversity?
They learn by example. When they leave my lab, I like
to think that there is a piece of me in each one of them.
If you look at the history of science, choose virtually
any scientist who has really made a name for herself or
himself, and look at the laboratory in which they began
their career, you will find that it is almost always with
someone equally or more prominent. These extraordinary
lineages exist in science, and they are no accident. They
simply reflect the fact that there are transferable elements
about how to do research, and how to do it well.
With regard to the first part of your question, I think
I do remember everyone who has worked in my lab. I
am so interactive, and for me it is all about the relation-
ships. Even though I have always been very focused on
specific goals, in an almost mystical sense, the older I
get, the more I realize that the science is almost sec-
ondary. It’s all about interacting with the people who
come to work with me, sharing a project, and struggling
with goals. For the most part, I form very close personal
relationships with almost everyone who comes to work
with me.
Your work has probed fundamental questions of
GPCR structure and function. Being the most
important single class of pharmaceutical targets, 
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how do you believe your research has influenced 
this fact?
When I began my work in the early 1970s, there was
no direct way to study any receptor. In those days, you
studied an adrenergic receptor by giving drugs to an an-
imal and seeing how it responded; you had to infer the
characteristics of the receptors based on very downstream
physiological effects. The first contribution I made, 30
years ago, was the development of direct radioligand
binding techniques for studying receptors, which allowed
you to study the receptors directly. That revolutionized
the business of how drugs are developed. Now drugs
could be screened simply based on their ability to com-
pete in radioligand binding assays. In fact, while we never
patented any of the receptors after we cloned them, we
did make available, through a nonexclusive licensing
mechanism at Duke, cultured cell lines that stably ex-
pressed all of the adrenergic and other receptors we had
cloned over the years. These licenses made a lot of money
for the institution.
In terms of drug development, that relatively simple
notion had a major impact. Once we had cloned the b2-
adrenergic receptor, in 1986, and it was the first seven-
membrane spanning drug target receptor to be cloned, we
quickly thereafter cloned eight or ten other receptors.
Based on that information, within a year or two, it be-
came clear that virtually all the seven-membrane span-
ning receptors were members of a superfamily. They
shared similar structures and amino acid sequences, and
we later showed that they shared a universal mechanism
of regulation in terms of desensitization.
That realization immediately accelerated the whole
field. Now people realized that they could clone what-
ever receptor or drug target they were interested in study-
ing simply by using homology techniques. The discov-
ery of one receptor led to the discovery of the next. In
our very first paper on the cloning of the b2-adrenergic
receptor—a classic paper in Nature in 1986—we specu-
lated in one of the last paragraphs that all GPCRs would
look like the b2-adrenergic receptor. Our prediction
turned out to be right.
What types of new drugs can you envision based 
on current knowledge of GPCR function and
distribution and the size of the gene family?
People quote different figures, but one is that 60% of
all prescription drugs sold in the world target GPCRs. All
those drugs have the same mechanism of action: they tar-
get the ligand binding site of the receptors, as either ag-
onists or antagonists. Agonists are things that stimulate,
like adrenaline, and antagonists are things like b-block-
ers or a-blockers. When I think about potential novel
ways of utilizing this information, I envision drugs that
target other aspects of receptors: not the ligand binding
site on the outside of the receptor, but maybe the inner
surfaces of the receptors where they interact with vari-
ous effector proteins, such as G proteins. If you could
block the interaction of the receptor with a G protein, you
would profoundly affect signaling. Currently, we silence
a receptor by blocking its active site so it cannot bind its
ligand. One of the main directions of my laboratory for
the past several years, and undoubtedly the main direc-
tion now, has to do with delineating novel signaling path-
ways in which the G proteins are either less important or
not important at all.
Wouldn’t compounds that target an effector binding
site tend to have less drug specificity?
I would think they would have less specificity, but
there are clinical conditions in which one might want to
target multiple receptors in a class. For example, consider
hypertension, in which many of the receptors involved in
hypertension (which control vascular reactivity) couple
to Gq, which is one of the G proteins. Angiotensin re-
ceptors couple to Gq, for example, and, from a commer-
cial perspective, some of the most useful drugs for treat-
ing hypertension are classical receptor blockers that block
angiotensin receptors. a-Adrenergic receptors also cou-
ple to Gq and can cause vasoconstriction. Endothelins,
too, couple to Gq and can lead to vasoconstriction, and
people are developing endothelin receptor blockers. Sup-
pose you had a generic way of inhibiting the coupling of
receptors to Gq. You could give one drug and maybe take
out ten different receptors that lead to increased vaso-
constriction and hypertension, rather than giving an an-
giotensin blocker, an endothelin blocker, etc. It may be
useful to be able to target panels of receptors.
Your laboratory has been a pioneer in many areas of
research related to GPCR signal transduction, one
example being your work on constitutively active
receptors. Please tell us a little about why this is
important and how knowledge of this mechanism
might lead to new drugs.
Constitutively active mutant receptors were something
we discovered about a dozen years ago. It was a com-
pletely serendipitous discovery. We were trying to make
receptors that were impaired in their activity and, quite
by accident, we made some that were superactive. Re-
ceptors are switches, and they are generally off in the ab-
sence of a stimulus. An agonist, such as adrenaline,
throws the switch and turns it on, changing the confor-
mation of the receptor. In general parlance, pharmacolo-
gists often talk about two different conformations of re-
ceptors, or basically classical allosteric theory applied to
receptors. They call the conformations R and R*, the in-
active and active conformations, respectively; they are in
equilibrium with each other. Agonists are drugs that bind
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with higher affinity to R* and push the equilibrium in that
direction.
We discovered that making certain changes in the re-
ceptors changed that equilibrium. For a typical receptor,
in the absence of agonist, the equilibrium is way in the
direction of R, with very little R*. However, certain mu-
tations could completely reverse that, putting the major-
ity of receptors in the active state even without an ago-
nist. Therefore, those mutations led to signaling, even in
the absence of a stimulus. From the perspective of drug
development, this was interesting, because we were able
to prove in a way that had not been possible before that,
rather than there being only two types of drugs, agonists
and antagonists, there had to be three. This had been
worked out by others years before, but had never been
demonstrated. The idea is that if you have two confor-
mations, R and R*, there are three possibilities for a drug:
one with preferentially higher affinity for R* (an agonist);
one with equal affinity for R and R* (an antagonist, which
does not change the equilibrium but prevents an agonist
from binding to the receptor); and one which has higher
affinity for R than for R*, which should turn the switch
off if it is already on. In most systems, the basal activity
of a receptor is so low that almost all receptors are in the
R conformation, and it would be very difficult to dem-
onstrate this third drug possibility. With a constitutively
active mutant receptor, which is already on in the absence
of any drug, you have a beautiful assay system for what
are now called negative antagonists or inverse agonists.
If you put such a drug on a constitutively active mutant
receptor, it shuts off its signal, whereas if you put a clas-
sical antagonist on the receptor, you saw no such turn-
off. This has direct implications for drug discovery in
terms of situations in which a constitutively active mu-
tation spontaneously forms, causing disease. You would
want to design a drug to turn it off.
Another area that your laboratory initiated is that of
“orphan” receptors. How did that come about?
This is another classical example of serendipity. The
story goes back to about 1985, when we had just cloned
the b2-adrenergic receptor. That was a huge watershed
in the field. We were beginning to think there would be
other receptors like it, but this was not yet known. One
of the first things we did was to try to clone the b1-ad-
renergic receptor. We took some human genomic DNA
and did a Southern blot, using as the probe the full-length
cDNA for the b2-adrenergic receptor. When we did the
Southern blot at high stringency, as you would expect,
we got only a single band, which was the gene for the
b2-adrenergic receptor. We then reduced the stringency,
expecting to see the progressive appearance of other
bands, which might represent other receptors. As we re-
duced the stringency of the Southern blots, we did pick
up one other band, but we never picked up any others,
for reasons I do not understand to this day. We assumed
that the new band was the b1 receptor, so we made a size-
selected genomic library, cloned out that band, sequenced
it, and found that it had seven-membrane spanning do-
mains. It looked very much like the b2 and we were quite
convinced it was the b1.
However, when we expressed it in cells and looked at
its ligand binding ability, it did not bind the b receptor
ligands, so we knew it wasn’t the b1. We published the
sequence anyway, because we knew that it was only the
second seven-membrane spanning receptor that had been
cloned. We called it G21 and it was, in fact, the very first
orphan receptor, because we did not know its ligand.
Nobody in the lab wanted to work on it, because they
didn’t know where to start. A year later, though, a new
postdoc (Anick Fargin) came to work in the lab. That’s
an important time, because it is only during those first
few months that people actually listen to me! I thought
it was a great project, and I sent her off to the library to
do some reading. I told her that what we know about the
receptor is that it looks like the b2 receptor and it weakly
binds b-receptor ligands, but not with the appropriate
specificity. She was to look in the literature and see if
there were any other receptors known to weakly bind 
b-receptor ligands. A day or two later, she came back
and reported that serotonin receptors could weakly bind
b-receptor ligands. We set up a competitive binding as-
say and showed that serotonin could compete for recep-
tor binding, and our orphan receptor turned out to be the
first serotonin receptor, the 5-HT1A. We published a pa-
per stating that this was the first orphan receptor and the
first orphan receptor “deorphanized.” The orphan recep-
tor field is now huge. Technically, of the 1,000 or more
seven-membrane spanning receptors that we know of
from the sequencing of the human genome, the over-
whelming majority are orphans.
The serendipitous nature of all this continued. The
band we had pulled out of the Southern blot and expected
to be the b1 had a sequence that was extraordinarily sim-
ilar to the b2 receptor. By the way, another fortunate
break for us was that most of the adrenergic receptors
have intronless genes. So we were able, right at the be-
ginning, to get complete protein sequences from genomic
clones. While we were sequencing this gene, I wanted to
make sure we had a cDNA for it, so we probed a very
good human placental phage cDNA library that I had ob-
tained from a friend of mine. We screened that cDNA li-
brary with what we thought was the b1 clone. To our hor-
ror, we pulled out a clone that, while clearly having
seven-membrane spanning domains, was different in se-
quence than our presumptive b1 receptor, and differed
from the b2 receptor. So now we had a third clone, an-
other orphan. Some people in the lab wanted to just put
it away, but I said, no, let’s finish the job. So we ex-
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pressed it, and it turned out to be the b1 receptor! Isn’t that
a crazy story? When the smoke cleared, we had cloned the
entire family of adrenergic receptors. We had stumbled
and bumbled, but in the end, it all worked out.
The visual signal transduction field has many times
foreshadowed discoveries of nonvisual signal
transduction. How has your laboratory leveraged 
this literature and, in some cases, added to it?
That’s a very good question. The reason that the vi-
sual system often gave clues as to what was going on in
mammalian biology is a simple one: the abundance of
these molecules in the visual system is thousands of times
greater than in other systems. We now appreciate the fact
that the visual signal transduction system works through
a series of components that are functionally and struc-
turally quite analogous to hormone receptor interactions.
For example, the light receptor rhodopsin (like the b re-
ceptor) signals to a G protein called tranducin, and there
is an effector enzyme, a cyclic GMP phosphodiesterase,
analogous to the mammalian adenylate cyclase. These
functional analogies were already appreciated in the early
1980s. In 1983, the sequence of rhodopsin was deter-
mined by Edman degradation (standard protein sequenc-
ing), which implies that there were grams of it available.
From bovine retina you can get an unbelievable amount
of rhodopsin. By comparison, to purify something like
the b2 receptor required 200,000-fold purification. We
spent years figuring out how to purify such a receptor.
When we published the sequence of the b2-adrenergic re-
ceptor in 1986, we showed that the receptor looked like
rhodopsin. Even though that should not have been a sur-
prise, because of the known functional analogies, it
shocked us and everybody else. Nobody really expected
that rhodopsin and the b receptor would look alike.
I was, maybe more than other people, tuned in to the
fact that the visual system might be providing clues. Let
me give you a specific example. We had found in the
early 1980s that the b2 receptor was regulated by phos-
phorylation, and that this occurred via a unique kinase,
which we named the b-adrenergic receptor kinase, or
bARK. One of my graduate students (Jeff Benovic) even-
tually purified bARK.
At the same time, several laboratories were studying a
mechanism for inactivation of rhodopsin and had identi-
fied a kinase that was involved in phosphorylating
rhodopsin, which resulted in its inactivation. They called
it rhodopsin kinase. In about 1986, the eye people found
that rhodopsin kinase could not work alone. It seemed to
require another molecule, a molecule that had been
known for years as 48K protein. It was a very abundant
molecule in the retina and it was extraordinarily im-
munogenic. It could lead to autoantibodies that could
cause retinal degeneration. They found that when you
stimulated the retina with light and rhodopsin became
phosphorylated, the 48K protein translocated to the reti-
nal membrane and helped to turn off the rhodopsin.
When they reported that in 1986, we were fretting over
the fact that the more we purified bARK, the more it lost
desensitizing activity. (We assayed bARK in a reconsti-
tuted system of b2-adrenergic receptor and Gs). Some in
the lab thought we were “barking” up the wrong tree, and
that the kinase had nothing to do with inactivating the re-
ceptor. I was convinced we were losing some accessory
factor. That is when the retina guys defined a role for the
48K protein, and they renamed it arrestin. I called the re-
searcher in Germany who had purified arrestin (Herman
Kuhn), and he sent me some of it. Sure enough, when we
added that to the assay, it completely restored the ability
of our highly purified bARK preparations to inactivate
the b receptor. That convinced me that there must be re-
lated effector molecules in nonvisual tissues. We went
searching for that and eventually discovered the b-ar-
restins, which function in an analogous way to their reti-
nal counterparts.
By the way, Jim Inglese’s connection to all this is that
his first project in my laboratory, after we had just cloned
the b-adrenergic receptor kinase, was to see if he could
clone rhodopsin kinase, and he did. We were the first
ones to clone rhodopsin kinase and we found that it
looked just like bARK, once again suggesting the exis-
tence of a gene family.
When molecular cloning began to build momentum
in the early 1980s, your laboratory forged a strategic
collaboration with Merck Research Laboratories to
clone the first mammalian GPCR, the b-adrenergic
receptor. What were the key elements that each
laboratory contributed to allow this landmark event
in biology to occur?
That collaboration began when a recent graduate of my
laboratory, Cathy Strader, went to work for Merck. She
was very impressed with some of their high tech capa-
bilities, such as a state-of-the-art protein microsequenc-
ing facility. Merck also had some good young molecular
biologists that were very involved with cloning. In con-
versations with Cathy, she may have suggested that we
collaborate, combining the expertise in our laboratory—
the only lab in the world to have purified a G protein-
coupled receptor—and the molecular biology capabilities
of Merck. We agreed that we would provide the purified
protein and Merck would do the cloning. Cathy cleaved
the purified protein with cyanogen bromide, separated the
peptides using HPLC, and then sequenced the peptides.
That yielded five individual peptide sequences totaling
about 80 amino acid residues.
Then the cloning work started; initially all of the
cloning was done at Merck. As the months went by,
Profile 237
though, and many libraries were screened, no headway
was being made. We never found any clones that con-
tained the peptides we knew were in the receptor. I be-
came increasingly impatient and frustrated with the
whole endeavor. I had a young cardiology physician sci-
entist in my laboratory named Brian Kobilka, and he was
very anxious to get involved in the cloning effort. He
made four one-week trips to Merck and learned the es-
sential aspects of cloning. Then we started working in
parallel with the people at Merck, but still we made no
progress.
One day, Brian made a crucial decision. He suggested
that we try to get a genomic clone instead of relying on
the cDNA libraries. We broached the subject with the peo-
ple at Merck, but they were not very enthused about it. So
Brian went ahead and made a genomic library. He sent the
genomic library to Merck, and both Merck and we
screened it. The first screen done in both places immedi-
ately pulled out really good-looking clones. Within a week,
we could see that our clones and Merck’s clones were the
same. Then the sequencing began. That went very quickly,
and to our amazement no introns were present in the ge-
nomic clone. We had the entire receptor in one open read-
ing frame, and one by one all of the peptides we had de-
duced from protein sequencing popped up.
Targeting of GPCRs with small molecules to mediate
hypertension has revolutionized health care for
cardiovascular disease. What is next in terms of drug
development based on GPCRs or their signaling
pathways? In particular, what is on the frontier, for
example, for psychiatric disorders and GPCRs?
My feeling is that a huge unexplored area has to do
with the systems that regulate GPCRs, and I have spent
much of my career studying this. Virtually all the drugs
we have today that target GPCRs target the ligand bind-
ing sites of the receptors. But, as I explained, there is a
universal mechanism that regulates the receptors, and I
think that system is a wonderful system for drug devel-
opment. We have made knockout animals of most of the
GPCR kinases and b-arrestins, and they have interesting
phenotypes. For example, I think that inhibitors of GRKs
(G protein-coupled receptor kinases) might be very use-
ful drugs. I see possible indications in heart failure,
asthma, Parkinson’s disease, etc. A number of drug com-
panies are currently working in this area. Knockout ani-
mals lacking b-arrestin 2 show a markedly prolonged and
intensified action of morphine; the morphine is not able
to desensitize the receptors, so you do not get tolerance.
So one frontier for the future is the development of drugs
targeting the systems that regulate these receptors.
When did you decide it was time to “leave” the lab
bench, and when was the last time you actually
demonstrated a laboratory technique to a trainee?
I set up the lab in 1973, and at the very beginning I
was very active at the bench. By 1975, I was not doing
much in the way of experiments. As the lab grew, I would
spend the early part of the day getting people started, go-
ing over their experiments with them, etc. So my own
experiments would start later and later in the day, until I
was starting my experiments at four o’clock in the after-
noon and I had to go around the lab trying to bum reagents
from people.
I would guess, though, that not very much goes on
in the lab that you do not know about.
That is correct. I basically live right here. I don’t chair
a department or lead a program, and I have refused such
things because what I love is being in the lab.
Is it true that you nearly pursued a career as a
pianist instead of going into medicine?
Absolutely not! I took piano lessons like any self-re-
specting middle class Jewish boy in the Bronx growing up
in the 1940s and 1950s, but as best I could tell, I was to-
tally devoid of talent, not to mention interest in the subject.
Your diet of whole grains and water is somewhat
legendary in scientific circles. What advice can you
give someone wishing to improve his or her dietary
lifestyle?
Avoid saturated fat and eat healthy foods—fruits and
vegetables. Avoid pastry and cakes. For a while, after I
had bypass surgery about 10 years ago, I was on a fairly
strict Ornish diet, and I am to this day a strict vegetar-
ian. In the last year or so, I have been liberalizing my
monounsaturated fats, adding some olive oil to my diet,
and my latest passion is peanut butter. I do not mean the
peanut butter you buy at the store, which has lots of hy-
drogenated fats in it. I go to a whole foods market that
has a machine with which you grind your own peanuts.
Thank you, Dr. Lefkowitz.
—Interview by Vicki Glaser
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